Africa has the highest incidence of mortality caused by infectious diseases, and remarkably does not have the capacity to manufacture vaccines that are essential to reduce mortality, improve life expectancy, and promote economic growth. Up to 99.9% of the vaccines come from sources outside the continent. Although GAVI (Global Alliance for Vaccines and Immunization) has significantly helped in the introduction of new vaccines in Africa however, its sustainability is questionable. Conversely, Africa with its high population and accelerating economic growth is an increasing potential market for vaccines, with the current vaccine consumption costs estimated at about $3 billion/annum and is expected to only grow with time as more people get vaccinated.
Just like the H1N1 influenza pandemic in 2009 and the Ebola outbreak in 2014, the current nCovid-19 pandemic has exposed the vulnerabilities of countries across the world, whether developed or developing, in dealing with a novel infectious disease through the disruption caused by the nCovid-19 pandemic in the normal daily lives of citizens, while negatively impacting the economies of countries globally. Due to this, the race to develop and produce nCovid-19 vaccine is in top gear across the world.
Equipped with the infrastructure and capacity to develop and produce vaccines, wealthy countries have directed tremendous resources towards developing vaccines and therapeutics to address the nCovid-19 pandemic and the race is on as to which company will deliver an effective SARS-CoV2 vaccine or treatment. Meanwhile, Africa is left out watching on the sideline and hoping that someone comes to its AID due to the failure to invest in the development of vaccine production infrastructure. Given all the resources Africa has, this a shame and a necessary and urgent tragedy that must be addressed immediately, seriously and aggressively by building the infrastructures needed internally with friends that are committed to such a course.
With a population of approximately 1.4 billion, just about 15% of the world population, Africa produces less than 0.1% of the world's vaccines it consumes. Its vaccine expenditure of about 3 billion dollars is sufficient to invest in vaccine production infrastructure that is sustainable given the projected economic growth of Africa, and the improvement in living standards that will accompany this as the continent’s GDP expands.
Through the application of Daktari Biotechnology's subunit vaccine & VLPs development technology, the company has started the development of a SARS-CoV2 subunit vaccine program. This technology will be extended to other human vaccine development programs like HPV, H1N1, Ebola and Yellow Fever among many others. The company will also develop a domestic animals vaccine development unit by deploying the VLPs technology.
There is no doubt that besides having a viable pharmaceutical industry in Africa, adding a viable vaccine production institute would have a very positive impact on Africa’s health systems and capacity to respond to the health needs of the people besides contribute to the improvement in the socioeconomic development of the continent. Daktari Biotechnology's aim is to be a major player in the vaccine space by developing, manufacturing and supplying 50-90% of the vaccines needed in the African continent within the next 10 years. The company invites investors to join it in the Africa Vaccines Venture to help us achieve our Mission and Vision.